Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197990 | 0.85 | KDM4E (0.67) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31486111 | 0.84 | GABRA1 (0.51) | GABRA1GABRB1GABRA3GABRB2GAA | |
| SCHEMBL21954408 | 0.83 | GAA (0.72) | GABRA1GABRB1GABRA3GABRB2GAA | |
| SCHEMBL12813732 | 0.82 | ALDH1A1 (0.62) | GABRA1GABRB1GABRA3GABRB2GAA | |
| SCHEMBL3199599 | 0.82 | GABRA1 (0.48) | GABRA1GABRB1GABRA3GABRB2ALDH1A1 | |
| SCHEMBL25263341 | 0.81 | GAA (0.54) | GABRA1GABRB1GABRA3GABRB2GAA | |
| SCHEMBL9434377 | 0.79 | ALDH1A1 (0.51) | GABRA1GABRB1GABRA3GABRB2GAA | |
| SCHEMBL31052359 | 0.79 | GAA (0.55) | GABRA1GABRB1GABRA3GABRB2GAA | |
| SCHEMBL25219268 | 0.79 | GAA (0.55) | GABRA1GABRB1GABRA3GABRB2GAA | |
| SCHEMBL15966771 | 0.79 | KDM5A (0.59) | GABRA1GABRB1GABRA3GABRB2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694057-B1 | LIPOXYGENASE INHIBITORS | STANFORD RES INST INT (US) | 2019-06-05 | — | — | EP | claimed |
| US-10646471-B2 | Lipoxygenase inhibitors | SRI INTERNATIONAL (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2694057-B1 | LIPOXYGENASE INHIBITORS | STANFORD RES INST INT (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170095450-A1 | Lipoxygenase Inhibitors | SRI INTERNATIONAL | 2017-04-06 | — | — | US | disclosed |
| EP-2694057-A1 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130345214-A1 | Lipoxygenase Inhibitors | SRI INTERNATIONAL, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012135133-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120184590-A1 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY | UNIVERSITY OF KANSAS (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2010118339-A2 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY | UNIVERSITY OF KANSAS (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7666897-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090023796-A1 | Analogs of Indole-3-Carbinol Metabolites as Chemotherapeutic and Chemopreventive Agents | SRI INTERNATIONAL (US) | 2009-01-22 | — | — | US | disclosed |
| US-7429610-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2008-09-30 | — | — | US | disclosed |
| US-7078427-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1623985-A2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventative agents | Sri International (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1530572-A2 | ANALOGS OF INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | Sri International (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6800655-B2 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL | 2004-10-05 | — | — | US | disclosed |
| US-20040157906-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | JONG LING (US) | 2004-08-12 | — | — | US | disclosed |
| WO-2004018475-A2 | ANALOGS OF INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | SRI INTERNATIONAL (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040043965-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | SRI INTERNATIONAL | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095450-A1 | Lipoxygenase Inhibitors | ALOX15B, ALOX12, ALOX15 | GABRA1 1815/4885GABRB1 1171/4885GABRA3 1707/4885 |
| US-20120184590-A1 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY | SCD, SCD5, IDO1 | GABRA1 3176/4885GABRB1 2764/4885GABRA3 1918/4885 |
| US-20130345214-A1 | Lipoxygenase Inhibitors | ALOX15B, ALOX12, ALOX15 | GABRA1 1815/4885GABRB1 1171/4885GABRA3 1707/4885 |
| US-10646471-B2 | Lipoxygenase inhibitors | ALOX15B, ALOX12, ALOX15 | GABRA1 1815/4885GABRB1 1171/4885GABRA3 1707/4885 |
| US-20090023796-A1 | Analogs of Indole-3-Carbinol Metabolites as Chemotherapeutic and Chemopreventive Agents | IDO1, CCND3, CCNA1 | GABRA1 4467/4885GABRB1 4453/4885GABRA3 3980/4885 |
| US-20040043965-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | IDO1, IDO2, TPH1 | GABRA1 4066/4885GABRB1 3636/4885GABRA3 4091/4885 |
| US-20040157906-A1 | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | IDO1, IDO2, TPH1 | GABRA1 4066/4885GABRB1 3636/4885GABRA3 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.